Amgen Inc. stock (US0311621009): EU approval for Imdelltra adds to oncology momentum

Amgen Inc. shares on the Nasdaq Global Select Market traded around USD 328 at the close on 06/02/2026, edging down roughly 0.3% on the day even as the European Commission granted marketing authorization for its small cell lung cancer therapy Imdelltra, giving the United States-based biotech group a fresh regulatory milestone in Europe, according to MarketBeat and other market data providers as of 06/02/2026.

On 06/02/2026, Amgen announced that the European Commission approved Imdelltra (tarlatamab) for adults with extensive-stage small cell lung cancer whose disease has progressed after platinum-based chemotherapy, following a positive opinion from the Committee for Medicinal Products for Human Use, as highlighted by coverage on Zacks and TradingView referencing the company’s communication and European regulators on 06/02/2026.TradingView/Zacks as of 06/02/2026

The approval in the European Union is based on phase III clinical data showing that tarlatamab significantly improved overall survival, with reports citing around a 40% reduction in the risk of death in the trial population compared to standard of care, underscoring the clinical relevance of the medicine in a hard-to-treat indication, according to recent summaries of the pivotal data as of 06/02/2026.GuruFocus as of 06/02/2026

The stock, which trades under the ticker AMGN on Nasdaq in the United States, remains a constituent of major U.S. equity benchmarks followed by international investors, and the latest regulatory progress in Europe adds to Amgen’s home-country narrative as one of the larger biotechnology names listed in New York.

The stock traded at about USD 328.26 on 06/02/2026 at the regular-session close on Nasdaq, with after-hours indications modestly lower at around USD 327.55, according to MarketBeat pricing data as of 06/02/2026.MarketBeat as of 06/02/2026

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

Amgen Inc.: core business model

Amgen focuses on discovering, developing, and commercializing innovative human therapeutics, with sales anchored in specialty medicines for serious diseases such as cancer, cardiovascular conditions, and inflammatory disorders that are marketed across major healthcare systems globally.

Amgen Inc. in peer comparison

In the global large-cap biotech universe, Amgen is often compared with U.S.-listed drug makers such as Gilead Sciences and Bristol Myers Squibb, which also generate substantial revenue from oncology and specialty therapies while competing for market share in key indications like hematologic malignancies and solid tumors.Bloomberg as of 06/02/2026

According to recent share-price snapshots, Gilead Sciences traded near the mid-USD 60 range in late May and early June 2026, while Bristol Myers Squibb hovered around the low-USD 40 zone over the same period, highlighting that Amgen currently commands a higher absolute share price and reflects a different mix of marketed products and pipeline assets compared with these peers.MarketWatch as of 05/31/2026MarketWatch as of 05/31/2026

Conclusion

The fresh European Commission marketing authorization for Imdelltra gives Amgen a new foothold in the treatment of extensive-stage small cell lung cancer, complementing its established presence in oncology and other specialty therapeutic areas. Against a peer set that includes Gilead Sciences and Bristol Myers Squibb, the company’s latest regulatory success underscores the role of pipeline execution and regional approvals in shaping investor focus on large-cap biotech stocks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.